Additional Information
Book Details
Abstract
For this issue, Dr. Michael Lim of Johns Hopkins and Dr. Isaac Yang of UCSF team up to deliver a packed issue on the latest developments in Immunotherapy. The issue covers hot topics such as immunostimulants, Passive Antibody Mediated Immunotherapy, Clinical Applications of A Peptide Based Vaccine, Challenges for Clinical Design of Immunotherapy Trials, The EGFRv3 Peptide Vaccine, Stem Cell Therapy and Dendritic Cell Vaccines, Dendritic Glioma Fusion Vaccine, Adoptive Cellular Immunotherapy, Virus Mediated Immunotherapy, and so much more.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contents | vii | ||
| Neurosurgery Clinics of North America | xiii | ||
| Preface | xiv | ||
| Chapter 1. Biologic Principles of Immunotherapy for Malignant Gliomas | 1 | ||
| TUMOR-ASSOCIATED IMMUNOSUPPRESSION | 1 | ||
| IMMUNOTHERAPY | 3 | ||
| MULTIMODALITY IMMUNOTHERAPY | 8 | ||
| SUMMARY | 8 | ||
| REFERENCES | 8 | ||
| Chapter 2. Mechanisms of Local Immunoresistance in Glioma | 17 | ||
| THE TUMOR IMMUNE MICROENVIRONMENT | 17 | ||
| SUMMARY | 24 | ||
| REFERENCES | 24 | ||
| Chapter 3. Glioblastoma-Derived Mechanisms of Systemic Immunosuppression | 31 | ||
| CAVEATS IMPORTANT TO CONSIDER WHEN EVALUATING PRIORWORK | 32 | ||
| OBSERVATIONS OFCELLULAR IMMUNITY IN PATIENTS WITHMALIGNANTGLIOMA | 33 | ||
| SUPPRESSIVE SURFACEMARKERS EXPRESSED ONGLIOMACELLS | 34 | ||
| GLIOMA-SECRETED FACTORS WITH POTENTIAL IMMUNOSUPPRESSIVEEFFECTS | 35 | ||
| ABNORMALITIES OFMONOCYTIC POPULATIONS IN PATIENTS WITHGBM | 36 | ||
| IDENTIFICATION AND CHARACTERIZATION OF T CELLSWITH REGULATORY CHARACTERISTICS IN GBM | 36 | ||
| SUMMARY | 38 | ||
| REFERENCES | 39 | ||
| Chapter 4. Microglia and Central Nervous System Immunity | 43 | ||
| ORIGIN OFMICROGLIA | 44 | ||
| MICROGLIA ASA SYSTEMOFACTIVE SURVEILLANCE | 44 | ||
| MICROGLIA ASMEDIATORS OFINFLAMMATION | 45 | ||
| MICROGLIA INCNS GLIOMAS | 46 | ||
| REFERENCES | 48 | ||
| Chapter 5. Immunostimulants for Malignant Gliomas | 53 | ||
| THEIMMUNE SYSTEM’S ROLEINCANCER GENESIS | 53 | ||
| IMMUNOSTIMULANTS | 54 | ||
| CYTOKINES | 54 | ||
| IL-2 | 55 | ||
| IL-4 | 55 | ||
| IL-12 | 56 | ||
| GRANULOCYTE^MACROPHAGE COLONY-STIMULATING FACTOR | 56 | ||
| TNF-a | 56 | ||
| MISCELLANEOUS CYTOKINES | 57 | ||
| IFN | 57 | ||
| PATHOGEN-ASSOCIATEDMOLECULAR PATTERN ASADJUVANTS | 58 | ||
| OLIGODEOXYNUCLEOTIDES | 59 | ||
| POLY-ICLC/HILTONOL | 59 | ||
| SUMMARY | 60 | ||
| REFERENCES | 60 | ||
| Chapter 6. Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas | 67 | ||
| MONOCLONAL ANTIBODIES | 67 | ||
| TARGET DETERMINATION OF PASSIVE ANTIBODY IMMUNOTHERAPY | 68 | ||
| ANTI-EGFR THERAPY | 68 | ||
| ANTI-EGFRVIII THERAPY | 70 | ||
| ANTIANGIOGENESIS THERAPIES | 70 | ||
| SEROTHERAPY AGAINST EXTRACELLULAR MATRIX PROTEINS | 71 | ||
| DISCUSSION | 72 | ||
| REFERENCES | 73 | ||
| Chapter 7. Interferon-gamma in BrainTumor Immunotherapy | 77 | ||
| INTERFERON-GAMMA ANDTHECELLCYCLE | 77 | ||
| INTERFERON-GAMMA SIGNALING | 78 | ||
| MAJOR HISTOCOMPATIBILITYCOMPLEX REGULATION BY INTERFERON-GAMMA | 78 | ||
| GENE THERAPYUSING INTERFERON-GAMMA TRANSFECTION | 79 | ||
| INTERFERON-GAMMA INHIBITSTUMOR ANGIOGENESIS | 80 | ||
| INTERFERON-GAMMA IN COMBINED IMMUNOTHERAPY | 80 | ||
| CLINICALTRIALS | 81 | ||
| SUMMARY | 81 | ||
| REFERENCES | 82 | ||
| Chapter 8. The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas | 87 | ||
| MALIGNANTGLIOMASAND PEPTIDE VACCINATION | 87 | ||
| EPIDERMALGROWTHFACTORVARIANT III | 88 | ||
| PRECLINICALTRIALSSTUDYING ACTIVE IMMUNIZATION WITH EPIDERMALGROWTH FACTORVARIANT III | 89 | ||
| CLINICALTRIALSSTUDYING ACTIVE IMMUNIZATION WITH EPIDERMALGROWTH FACTORVARIANT III | 90 | ||
| DISCUSSION | 91 | ||
| REFERENCES | 92 | ||
| Chapter 9. Clinical Applications of a Peptide-Based Vaccine for Glioblastoma | 95 | ||
| IMMUNOTHERAPY | 95 | ||
| IMMUNE SYSTEM COMPONENTS | 97 | ||
| CENTRAL NERVOUS SYSTEM IMMUNE PRIVILEGE | 97 | ||
| TUMOR-RELATED IMMUNE SUPPRESSION | 99 | ||
| MONOCLONAL ANTIBODIES AS THERAPEUTICS | 99 | ||
| TUMOR-ASSOCIATED AND TUMOR-SPECIFIC ANTIGENS | 100 | ||
| PEPTIDE VACCINATION TRIALS | 102 | ||
| EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III VACCINE TRIALS | 103 | ||
| SUMMARY | 104 | ||
| REFERENCES | 105 | ||
| Chapter 10. Heat Shock Proteins in Glioblastomas | 111 | ||
| VACCINES AND IMMUNOTHERAPY | 111 | ||
| HSP CANCER VACCINES | 115 | ||
| MORE EFFICIENT ANTIGEN PRESENTATION ON MHC | 116 | ||
| REFERENCES | 118 | ||
| Chapter 11. The Role ofTregs in Glioma-Mediated Immunosuppression: PotentialTarget for Intervention | 125 | ||
| BIOLOGIC ROLEOF TREGS IN PATIENTS WITHGLIOMA | 127 | ||
| PROGNOSTIC SIGNIFICANCEOF TREGS IN PATIENTS WITHGLIOMA | 127 | ||
| MECHANISMS OFMODULATINGTREG RESPONSES | 128 | ||
| FUTUREDIRECTIONS | 131 | ||
| REFERENCES | 132 | ||
| Chapter 12. Dendritic Cell Vaccines for Brain Tumors | 139 | ||
| ANIMALMODELS | 142 | ||
| CLINICALTRIALS | 142 | ||
| CURRENT STATUS OFDC VACCINES FOR BRAIN TUMORS | 145 | ||
| SUMMARY | 154 | ||
| REFERENCES | 154 | ||
| Chapter 13. Glioma Stem Cell Research for the Development of Immunotherapy | 159 | ||
| CSC BRAIN TUMOR STEM CELL AND CD133 CSCS | 159 | ||
| GLIOMA CSCS AND CLINICAL TREATMENT | 160 | ||
| TARGETING SIGNALING PATHWAYS IN CSCS | 161 | ||
| TARGETING CSCS USING PASSIVE IMMUNOTHERAPY | 161 | ||
| TARGETING CSCS USING ACTIVE IMMUNOTHERAPY | 162 | ||
| SUMMARY | 163 | ||
| REFERENCES | 163 | ||
| Chapter 14. Virally Mediated Immunotherapy for BrainTumors | 167 | ||
| VIRALTHERAPYFOR BRAIN TUMORS | 167 | ||
| IMMUNECOMPARTMENTS, BRAIN TUMORS, ANDVIRUSES | 169 | ||
| IMMUNITYANDTHERAPEUTIC ANTICANCER VIRUSES | 170 | ||
| SUPPRESSING ANTIVIRAL IMMUNITY DURING ONCOLYTIC VIRALTHERAPYOFGLIOMA | 172 | ||
| ENHANCING ANTIGLIOMA IMMUNITY THROUGH ONCOLYTIC VIRALTREATMENT | 173 | ||
| IMMUNOTHERAPEUTIC TARGETINGOF VIRAL ANTIGENSASTHERAPY | 176 | ||
| SUMMARY | 176 | ||
| REFERENCES | 177 | ||
| Chapter 15. Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy | 181 | ||
| TREATMENT-EFFECT NECROSIS | 181 | ||
| PSEUDOPROGRESSION | 182 | ||
| IDENTIFYINGTREATMENT EFFECTON IMAGING AFTER IMMUNOTHERAPY | 182 | ||
| RADIOGRAPHIC ADVANCES IN DISTINGUISHING TUMOR RECURRENCEFROMTREATMENT EFFECT | 183 | ||
| MANAGEMENT OFPATIENTS WITH RADIOGRAPHICCHANGES AFTER GBM RESECTIONS | 184 | ||
| SUMMARY | 184 | ||
| REFERENCES | 184 | ||
| Chapter 16. Immunotherapy Combined with Chemotherapy in the Treatment of Tumors | 187 | ||
| POSSIBLE MECHANISMS OF ACTION OF COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY | 188 | ||
| LABORATORY STUDIES | 188 | ||
| CLINICAL STUDIES | 189 | ||
| SUMMARY | 190 | ||
| REFERENCES | 190 | ||
| Chapter 17. Monitoring Immune Responses After Glioma Vaccine Immunotherapy | 195 | ||
| T-CELL MEDIATED RESPONSES AND T-CELL FUNCTION ASSAYS | 195 | ||
| ENZYME-LINKED IMMUNOSORBENT ASSAY | 196 | ||
| ELISPOT | 196 | ||
| TETRAMER ANALYSIS | 196 | ||
| CHROMIUM RELEASE ASSAY | 196 | ||
| DISCUSSION | 197 | ||
| REFERENCES | 198 | ||
| Chapter 18. Challenges in Clinical Design of Immunotherapy Trials for Malignant Glioma | 201 | ||
| TARGET IDENTIFICATION | 203 | ||
| IMMUNOMODULATION | 205 | ||
| ACTIVEIMMUNOTHERAPY | 208 | ||
| SUMMARY | 209 | ||
| ACKNOWLEDGMENTS | 210 | ||
| REFERENCES | 210 | ||
| Index | 215 |